Foley Represents NOMADX Holdings in Launch to Commercialize Its Biological and Chemical Detection Platform

Foley & Lardner LLP advised NOMADX Holdings LLC, a private company pioneering new technologies for biological and chemical detection, in its launch to commercialize a portfolio of innovative products that will enable faster, more accurate portable testing in food, water, air safety, and clinical applications.

Powered by technology licensed from Johns Hopkins University, NOMADX Holdings’ platform represents a significant advancement in detection technology. The platform utilizes a patented surface coating applied to silicon chips using metallic nanoparticles, resulting in enhanced detection sensitivity and speed. Internal validation studies have demonstrated single-molecule detection levels and rapid results comparable to traditional PCR testing.

NOMADX Holdings aims to address critical public health and safety challenges through its platform. The first commercial application of the platform will focus on enabling on-site testing for the food safety and public water utilities industries, aiming to prevent foodborne illnesses and ensure safe drinking water for communities worldwide.

The Foley deal team was led by partner David Sanders and special counsel Timothy Grasser and included associate Sherwin Yee (M&A) and partners James Howard (Tax) and Michael Dubner (IP).